ADEL-Y01
ADEL-Y01 is a humanized and parental murine blood-brain barrier-penetrating monoclonal antibody against tau-acK280. ADEL-Y01 specifically recognizes tau-acK280 and its surrounding residues, mediates the neutralization and phagocytosis of acetylated tau aggregates, and interferes with the activity of pathological tau protein. ADEL-Y01 prevents the progression of tauopathies, increases neuronal survival rate, reduces tau-related pathological changes, and improves memory impairment. ADEL-Y01 can be used in research related to Alzheimer's disease and tauopathies.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vivo
ADEL-Y01 (50 mg/kg; i.p.; weekly; 3 months) ameliorates behavioral deficits and pathological tau changes in Tau-P301L-transgenic mice, with antibody crossing the blood-brain barrier to target tau-acK280[2].
ADEL-Y01 (50 mg/kg; i.p.; weekly; 3 months) improves cognitive performance and reduces tau aggregates in Tau-P301S-transgenic mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Tau-P301L-transgenic (backcrossed to C57BL/6J over five generations; male and female; 8 months old at start)[2]
-
Dosage:1.9 mg/mL
-
Administration:i.c.v.; continuous infusion; 28 days
-
Result:Improved performance in nest building, Y-maze, water maze, and grip strength tests.
Reduced insoluble tau levels in mouse brains.
Decreased total tau (tau-5), tau-pS396, and tau-acK280 levels in cortex lysate western blots.
Normalized increased phosphorylated tau levels via immunohistochemistry.
Showed a non-statistically significant trend toward reversal of tau-Tg-associated decreases in synaptic proteins (PSD95, synapsin-1).
-
Animal Model:Tau-P301L-transgenic (backcrossed to C57BL/6J over five generations; 7 or 14 months old at start)[2]
-
Dosage:50 mg/kg
-
Administration:i.p.; weekly; 3 months
-
Result:Improved performance in nest building, Y-maze, and Morris water maze tests.
Entered the brain and bound to tau-acK280.
Decreased total tau (tau-5), tau-pT231, and tau-acK280 aggregate levels in semi-denatured western blots of cortex lysates.
Showed a non-statistically significant trend toward reversal of tau-Tg-associated decreases in synaptic proteins (PSD95, synapsin-1).
-
Animal Model:Tau-P301S-transgenic (backcrossed to C57BL/6J over five generations; 5 months old at start)[2]
-
Dosage:5 mg/kg; 50 mg/kg
-
Administration:i.p.; weekly; 3 months
-
Result:Improved performance in the Morris water maze test at 50 mg/kg dose.
Decreased levels of total tau (tau-5) and tau-acK280 monomers and oligomers/aggregates in semi-denatured western blots of formic acid-fractionated hippocampus lysates at 50 mg/kg dose.
No quantitative results reported for the 5 mg/kg dose.
Gene ID
Accession
Target
Tau
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Phagocytosis Functional Assay
A phagocytosis functional assay measures the ability of phagocytic cells, such as neutrophils, macrophages, monocytes, or microglia/macrophages, to bind and internalize particulate targets including bacteria, yeast particles, beads, or myelin particles. Fluorescent flow-cytometry assays detect target uptake as fluorescence associated with gated phagocytes, while pH-sensitive dyes such as pHrodo increase signal in acidic phagosomal compartments and therefore preferentially report internalized particles rather than particles remaining outside the cell. Microscopy or high-content imaging can be used to confirm intracellular localization and, in some protocols, to follow uptake kinetics.
-
Serum-Free B27/Neurobasal Neuronal Maintenance Culture
Serum-free B27/Neurobasal culture is a defined neuronal maintenance method designed to support dissociated primary neurons while limiting serum-driven glial expansion; the readout is sustained neuronal survival, neurite extension, neuronal marker expression, synapse formation, and, when measured, electrophysiological or calcium activity. B27/Neurobasal was optimized in embryonic rat hippocampal neurons, where B27 supported >60% survival after 4 days above 160 plated cells/mm2 and Neurobasal reduced glial growth to <0. 5% by immunocytochemistry; later studies extended the approach to cortex, striatum, substantia nigra, septum, cerebellum, and dentate gyrus neurons.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)